Crossmark

Complete morphologic response to gilteritinib in ALK-rearranged acute myeloid leukemia

Published Online: 2024-09-10

Authors

Adashek, Jacob J. https://orcid.org/0000-0003-4272-312X
Brodsky, Max

Levis, Mark J.
License Information

Text and Data Mining valid from 2024-09-10

Version of Record valid from 2024-09-10
More Information

Article History

Received: 26 February 2024

Accepted: 30 August 2024

First Online: 10 September 2024

Competing interests

: J.J.A. serves on the advisory board of CureMatch Inc. and serves as a consultant for datma. M.B. has no relevant competing interests to disclose. M.J.L. declares Astellas (Laboratory Service Agreement) and Astellas, Daiichi-Sankyo, Abbvie, Bristol Myers Squibb, Amgen, Glaxo-Smith Kline, Jazz, Schroedinger, Syndax, Takeda (Consultant/Advisor/clinical trial funding).

Document is current